Marquis Who's Who Honors Howard E. Lambert, PhD, PE, as a Top Engineer in Nuclear Engineering
About Dr. Lambert
Before founding FTA Associates, Dr. Lambert worked at the Lawrence Livermore National Laboratory, providing him with invaluable experience and exposure to leading field experts who greatly influenced his professional journey. During his tenure, he gained knowledge that significantly shaped his teaching approaches. He has taught various college-level courses on probabilistic risk assessment, system safety and fault tree analysis.
Dr. Lambert's academic achievements have been foundational to his success. He graduated from Youngstown State University with a bachelor's degree in mathematics in 1968 and another bachelor's degree in chemical engineering in 1969. Later in his career, he earned a Master of Engineering in nuclear engineering from the University of Florida and a Doctor of Philosophy in nuclear engineering from the University of California Berkeley.
In addition to his academic achievements, Dr. Lambert holds a professional engineering license and certifications in safety and nuclear engineering, highlighting his dedication to continuous learning and passion for collaborating with other industry experts.
Professional Pursuits and Achievements
Among his professional accomplishments, Dr. Lambert is a contributing writer to several professional publications and maintains a personal website that features his extensive body of published work as a seasoned researcher. He has also published several technical articles in system safety, reliability and security analysis, including 'Introduction to Fault Tree Analysis' with Professor Richard Barlow.
Dr. Lambert has received several prestigious awards for contributions to the field, including the Atomic Energy Commission Fellowship Awards at the University of California Berkeley and the University of Florida. He is also the recipient of the Paul C. Luginbill Chemical Engineering Award from Youngstown State University.
Dr. Lambert credits his professional growth and success to the insights he has gained while working alongside esteemed colleagues at Lawrence Livermore National Laboratory and other institutions. Looking ahead, he aims to continue developing his website, teaching and consulting, keeping his mind active and engaged in an evolving industry.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms worldwide. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
LEO Pharma Delivers 7% Revenue Growth at CER in H1 2025 and Achieves Key Milestones Enabling Future Growth
BALLERUP, Denmark--(BUSINESS WIRE)--In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted EBITDA margin in 2025 towards the upper-end of previously communicated expectations. In July, the FDA approval of Anzupgo® and partnership with Boehringer Ingelheim for SPEVIGO®, marked major strategic milestones demonstrating LEO Pharma's commitment to advancing innovation in dermatology. Highlights LEO Pharma's revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza ® /Adbry ® and Anzupgo ®, which combined had a revenue increase of 51% (CER). Sales in the Critical Care portfolio (formerly called 'Thrombosis') declined by 3% (CER) year-on-year, affected by the reversal of sales discounts in the same period last year. Operating profit improved significantly, with adjusted EBITDA reaching DKK 1,456 million in H1 2025, reflecting a margin of 21% (H1 2024: 9%) excluding the STAT6 partnership upfront payment from Gilead received in January and other non-recurring items. Net profit for H1 2025 was DKK 1,977 million (H1 2024: negative DKK 761 million), including non-recurring items. Free cash flow was DKK 1,469 million for H1 2025 (H1 2024: negative DKK 779 million), and net interest-bearing debt was reduced to DKK 9,676 million (YE 2024: DKK 11,115 million). Excluding M&A, free cash flow was negative DKK 158 million driven by timing and non-recurring one-offs. On 23 July, LEO Pharma received FDA approval of Anzupgo® (delgocitinib) for the treatment of chronic hand eczema, enabling launch of the product in the U.S. by Q3 2025 as the first and only topical pan-JAK inhibitor. Additionally, LEO Pharma on 9 July announced positive interim results from the phase 3 ADHAND trial for Adtralza®/Adbry® (tralokinumab). On 14 July, LEO Pharma announced a partnership with Boehringer Ingelheim, granting LEO Pharma an exclusive global license for the development and commercialization of SPEVIGO® (spesolimab), a first-in-class IL-36R antagonist already approved and marketed for generalized pustular psoriasis (GPP). The partnership aims to accelerate and broaden access for patients by leveraging LEO Pharma's global dermatology platform. The transaction is expected to close in H2 2025 with SPEVIGO® set to become the third Strategic brand in LEO Pharma's portfolio, alongside Adtralza®/Adbry® and Anzupgo®. For the 2025 outlook, group revenue growth is now expected to be 7-9% at CER (previously: 6-9%) and the adjusted EBITDA margin is now expected to be 16-18% (previously: 15-18%). This reflects the FDA approval of Anzupgo® and year-to-date business performance. The outlook does not include any impact from the partnership for SPEVIGO®, pending closing of the transaction. LEO Pharma is in its strongest position in years – financially, strategically, and in terms of our portfolio and pipeline activities. The FDA approval of Anzupgo® represents a major step forward, and together with the addition of SPEVIGO® to our portfolio, we are further unlocking the value of our global platform, highlighting our commitment to driving innovation for patients.' CEO Christophe Bourdon. About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Head-quartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit
Associated Press
4 hours ago
- Associated Press
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-derived medicinal products. This MOU formalizes and deepens a relationship that began in 2015, when GC Biopharma supported TRCS to establish a plasma fractionation facility in Thailand, and reflects the ongoing strategic collaboration between the two parties. Under the terms of the MOU, GC Biopharma and TRCS will jointly develop and operate on-site training and exchange programs for local production personnel. These programs aim to transfer GC Biopharma's advanced manufacturing technologies and expertise to support the development of local capabilities. In addition, both parties intend to continue identifying and expanding collaborative opportunities that align with their respective strengths and interests. The scope of cooperation will be gradually broadened to include potential joint projects such as the transfer of new processing technologies for plasma by-products and other strategic projects. 'This MOU is a significant step in broadening the reach of GC Biopharma's advanced technology and production standards across Asia,' said Hyoungjun Park, Vice President of GC Biopharma. 'Through our collaboration with the TRCS, we aim to achieve mutual growth while contributing to the public good.' 'Enhancing our personnel's capabilities through specialized training and direct knowledge transfer from GC Biopharma is essential to maintaining the quality, safety, and continuity of plasma-derived medicinal products production in Thailand,' said Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre, TRCS. 'This collaboration not only supports the human resource development but also represents an important step for technology transfer and playing a vital role in strengthening the country's pharmaceutical and public health security.' Meanwhile, GC Biopharma continues to expand its global plasma-derived therapeutics business. In addition to entering the U.S. immunoglobulin market in 2024, the company is actively building partnerships in Southeast Asia, where domestic fractionation capabilities remain limited. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kim [email protected] Yelin Jun [email protected] Yoonjae Na [email protected] View original content to download multimedia: SOURCE GC Biopharma
Yahoo
6 hours ago
- Yahoo
Mitsubishi Electric's Net Zero Energy Building Test Facility "SUSTIE" is Asian Regional Winner in ASHRAE Technology Awards Program
TOKYO, August 18, 2025--(BUSINESS WIRE)--Mitsubishi Electric Corporation, Mitsubishi Jisho Design Inc. and Waseda University jointly announced today that Mitsubishi Electric's Net Zero Energy Building Test Facility "SUSTIE," located in Kamakura, Kanagawa prefecture, was selected as Regional Winner (Regional Level Technology Awards 2025-2026 Regional Winner) in the Commercial Buildings (new) category of the ASHRAE® Technology Awards program. Organized by the Asian Region (ASHRAE Region XIII) of The American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE), the program is one of the world's biggest technology award initiatives focusing on environmentally friendly building design. ASHRAE Technology Awards, one of the world's biggest technology awards program for environmentally friendly buildingsThe ASHRAE Technology Awards program, held annually since 1999, is one of the world's biggest such programs, recognizing innovative environmentally-friendly buildings for their occupant comfort, indoor air quality and energy conservation, with evaluations based on the building's verifiable operating data. In the Asian region selection, SUSTIE was the Regional Winner in the New Commercial Buildings category at the ASHRAE Region XIII Chapters Regional Conference. This award will ensure SUSTIE is reviewed by ASHRAE as a representative project of the Asian region in the worldwide selection process. Mitsubishi Electric, Mitsubishi Jisho Design and Waseda University will continue in their efforts to realize "the World's Most Environmentally Friendly Building." ASHRAE: American Society of Heating, Refrigerating and Air-Conditioning Engineers (based in Atlanta, US) was established in 1894, and is the largest international body focusing on air conditioning. It has more than 50,000 members across more than 130 nations. For the full text, please visit: View source version on Contacts Mitsubishi Electric Corporation Public Relations DivisionE-mail: Mitsubishi Jisho Design Inc. Corporate Planning Department Public Relations OfficeTEL: +81-3-3287-5001 Waseda University Public Relation OfficeTEL: +81-3-3202-5454 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
